trending Market Intelligence /marketintelligence/en/news-insights/trending/d8Nh7zavXQgUS6ysaOpzaw2 content esgSubNav
In This List

Alnylam Pharmaceuticals director to resign

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Alnylam Pharmaceuticals director to resign

Kevin Starr plans to resign as director of Alnylam Pharmaceuticals Inc., effective March 31.

The decision is not as a result of any disagreement with the company or any matter relating to its operations, policies or practices, Alnylam said in a securities filing.

Cambridge, Mass.-based Alnylam Pharmaceuticals is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics based on RNA interference.